A Phase III study (CheckMate 238) of adjuvant immunotherapy with nivolumab (NIVO) versus ipilimumab (IPI) after complete resection of stage IIIb/c or stage IV melanoma (MEL) in patients (pts) at high risk for recurrence

類似資料

• ATIM-17. A PHASE I TRIAL OF HYPOFRACTIONATED STEREOTACTIC IRRADIATION (HFSRT) COMBINED WITH NIVOLUMAB (NIVO), IPILIMUMAB (IPI) AND BEVACIZUMAB (BEV) IN PATIENTS (PTS) WITH RECURRENT HIGH GRADE GLIOMAS
  著者:: Sahebjam, Solmaz, 等
  出版事項: (2019)
• Adjuvant therapy with nivolumab versus ipilimumab after complete resection of stage III/IV melanoma: Japanese subgroup analysis from the phase 3 CheckMate 238 study
  著者:: Yokota, Kenji, 等
  出版事項: (2019)
• Immuno-oncology safety education experience: Key lessons from ipilimumab (IPI)
  著者:: Bartell, Heddy, 等
  出版事項: (2015)
• Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma: Results From the Phase IIIb/IV CheckMate 511 Trial
  著者:: Lebbé, Celeste, 等
  出版事項: (2019)
• Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy
  著者:: Eggermont, A.M.M., 等
  出版事項: (2016)